Compare · MYOV vs ROIV
MYOV vs ROIV
Side-by-side comparison of Myovant Sciences Ltd. (MYOV) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYOV and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ROIV is the larger of the two at $22.48B, about 19.2x MYOV ($1.17B).
- ROIV has more recent analyst coverage (18 ratings vs 7 for MYOV).
- Company
- Myovant Sciences Ltd.
- Roivant Sciences Ltd.
- Price
- $26.99+0.00%
- $31.25-0.49%
- Market cap
- $1.17B
- $22.48B
- 1M return
- -
- -3.59%
- 1Y return
- -
- +171.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 7
- 18
Myovant Sciences Ltd.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest MYOV
- SEC Form 15-12G filed by Myovant Sciences Ltd.
- SEC Form EFFECT filed by Myovant Sciences Ltd.
- SEC Form EFFECT filed by Myovant Sciences Ltd.
- SEC Form 25-NSE filed by Myovant Sciences Ltd.
- SEC Form 4: Valente Nancy returned 3,673 shares to the company, closing all direct ownership in the company (withholding obligation)
- SEC Form 4: Potter Myrtle S returned 3,673 shares to the company, closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Merendino Lauren returned 169,538 shares to the company, closing all direct ownership in the company to satisfy withholding tax
- SEC Form S-8 POS filed by Myovant Sciences Ltd.
- SEC Form 4: Mehra Uneek returned 202,696 shares to the company, closing all direct ownership in the company (for tax liability)
- SEC Form S-8 POS filed by Myovant Sciences Ltd.
Latest ROIV
- President & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85, sold $6,054,000 worth of shares (200,000 units at $30.27) and covered exercise/tax liability with 34,483 shares, decreasing direct ownership by 2% to 1,613,063 units (SEC Form 4) (withholding obligation)
- CFO Pulik Richard covered exercise/tax liability with 18,962 shares, decreasing direct ownership by 6% to 278,549 units (SEC Form 4) to satisfy withholding tax
- SEC Form S-8 filed by Roivant Sciences Ltd.
- SEC Form 10-K filed by Roivant Sciences Ltd.
- Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
- Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.